Moderna (MRNA) Misses Q3 EPS by 228c

Moderna (NASDAQ: MRNA) reported Q3 EPS of $2.53, $2.28 worse than the analyst estimate of $4.81. Revenue for the quarter came in at $3.36 billion versus the consensus estimate of $4.63 billion.

For earnings history and earnings-related data on Moderna (MRNA) click here.

You May Also Be Interested In

• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• Creatd files Form S-1 and reports Q1 2026 financial results
• Moderna's mRNA flu vaccine backed by FDA advisers